Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812812 | 0.84 | SLC6A2 (0.35) | PTPN1 | |
| SCHEMBL4792261 | 0.82 | HRH3 (0.52) | CNR2 | |
| SCHEMBL2887550 | 0.81 | SLC6A4 (0.42) | HDAC6HDAC1HDAC8 | |
| SCHEMBL4792573 | 0.77 | CNR2 (0.43) | HDAC1CNR2 | |
| SCHEMBL4792135 | 0.76 | HDAC6 (0.40) | HDAC6CNR2F2 | |
| SCHEMBL3844239 | 0.75 | NPC1 (0.36) | — | |
| SCHEMBL4793844 | 0.73 | HRH3 (0.39) | HDAC6HDAC1HDAC10HDAC3HDAC2 | |
| SCHEMBL4762113 | 0.73 | CDK9 (0.43) | — | |
| SCHEMBL4791558 | 0.73 | HRH3 (0.37) | HDAC6HDAC1 | |
| SCHEMBL12938904 | 0.67 | HDAC6 (0.69) | HDAC6HDAC1HDAC10HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | claimed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | claimed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | claimed |
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | HDAC6 586/4885HDAC1 701/4885HDAC10 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.